Groleau C, Morin S N, Vautour L, Amar-Zifkin A, Bessissow A
1Hematology Residency Program, McGill University, Montreal, Canada.
2Department of Medicine, Division of General Internal Medicine, McGill University Health Centre, Montreal, Canada.
Perioper Med (Lond). 2018 Jun 8;7:10. doi: 10.1186/s13741-018-0092-9. eCollection 2018.
Perioperative administration of corticosteroid is common and variable. Guidelines for perioperative corticosteroid administration before non-cardiac non-transplant surgery in patients with current or previous corticosteroid use to reduce the risk of adrenal insufficiency are lacking. Perioperative use of corticosteroid may be associated with serious adverse events, namely hyperglycemia, infection, and poor wound healing.
To determine whether perioperative administration of corticosteroids, compared to placebo or no intervention, reduces the incidence of adrenal insufficiency in adult patients undergoing non-cardiac surgery who were or are exposed to corticosteroids.
We searched MEDLINE via Ovid and PubMed, EMBASE via Ovid, and the Cochrane Central Register of Controlled Trials, all from 1995 to January 2017.
We included randomized controlled trials (RCTs), cohort studies, case-studies, and systematic reviews involving adults undergoing non-cardiac non-transplant surgery and reporting the incidence of postoperative adrenal insufficiency.
Two authors independently assessed studies' quality and extracted data. A descriptive and bias assessment analysis was performed.
Two RCTs (total of 37 patients), five cohort studies (total of 462 patients), and four systematic reviews were included. Neither RCT showed a significant difference in the outcome. This result was like that of the five cohort studies. The quality of the evidence was low.
The current use of perioperative corticosteroid supplementation to prevent adrenal insufficiency is not supported by evidence. Given the significant studies' limitations, it is not possible to conclude that perioperative administration of corticosteroids, compared to placebo, reduces the incidence of adrenal insufficiency.
围手术期使用皮质类固醇很常见且存在差异。目前尚无关于在当前或既往使用皮质类固醇的患者进行非心脏非移植手术前围手术期使用皮质类固醇以降低肾上腺功能不全风险的指南。围手术期使用皮质类固醇可能与严重不良事件相关,即高血糖、感染和伤口愈合不良。
确定与安慰剂或无干预相比,围手术期给予皮质类固醇是否能降低接受非心脏手术且曾使用或正在使用皮质类固醇的成年患者肾上腺功能不全的发生率。
我们通过Ovid检索了1995年至2017年1月期间的MEDLINE、通过Ovid检索了EMBASE以及Cochrane对照试验中央注册库。
我们纳入了随机对照试验(RCT)、队列研究、病例研究以及涉及接受非心脏非移植手术的成年人并报告术后肾上腺功能不全发生率的系统评价。
两位作者独立评估研究质量并提取数据。进行了描述性和偏倚评估分析。
纳入了两项RCT(共37例患者)、五项队列研究(共462例患者)以及四项系统评价。两项RCT均未显示出结果上的显著差异。五项队列研究的结果也是如此。证据质量较低。
目前围手术期补充皮质类固醇以预防肾上腺功能不全的做法缺乏证据支持。鉴于研究存在显著局限性,无法得出与安慰剂相比,围手术期给予皮质类固醇能降低肾上腺功能不全发生率的结论。